Table 1.
Deposition Fraction as a Percentage of Emitted Dose
| Aerosols | DFinlet | DFwye | DFETT | DFdevicea | DFfilterb |
|---|---|---|---|---|---|
| CM wye | |||||
| MMAD=880 nm | 3.1 (1.1)d | 7.2 (3.5)d | 2.1 (0.5)d | 12.4 (4.2)d | 87.6 (4.2)d |
| MMAD=1.78 μm | 2.9 (1.2)d | 8.0 (4.5)d | 9.3 (1.7)d | 20.2 (5.0)d | 79.8 (5.0)d |
| MMAD=4.9 μm | 5.6 (1.75) | 25.6 (0.9) | 40.7 (2.1) | 87.7c (2.1) | 12.3 (2.1) |
| SL wye | |||||
| MMAD=880 nm | 3.7 (1.7) | 1.6 (1.0)e | 1.9 (0.5) | 7.2 (2.9)e | 92.8 (2.9)e |
| MMAD=1.78 μm | 2.5 (1.4) | 1.6 (0.9)e | 6.7 (0.7)e | 10.9 (2.2)e | 89.1 (2.2)e |
The table presents mean (SD) deposition fraction (DF) as a percentage of dose emitted from the mixer (880-nm and 1.78-μm aerosols) or nebulizer (4.9-μm aerosol) at a steady-state flow rate of 5 L/min for the commercial (CM) and streamlined (SL) cases based on in vitro experiments.
Total device DF.
Equal to the emitted dose (ED) from the ETT.
Value includes a DF of 15.9% in the neonatal T-connector, which was not present in the other aerosol cases.
Statistically significant difference in DF compared with the DF observed for the 4.9-μm MMAD aerosol (p<0.05; t test).
Statistically significant difference in DF for the SL setup compared with the DF observed for the same sized aerosol delivered through the CM setup (p<0.05; t test).